Introduction
Type 2 diabetes is associated with a two-to four-fold increased risk of cardiovascular events. 1 Typically, overt diabetes is preceded by impaired glucose tolerance (IGT), which is characterized by hyperglycaemia after a glucose challenge. Previously published data suggest that already this pre-diabetic state is associated with an adverse macrovascular outcome. 2, 3 However, unequivocal data on the prognostic value of postchallenge hyperglycaemia in high-risk patients are not available yet. The GAMI trial (Glucose tolerance in patients with Acute Myocardial Infarction) suggested that post-challenge hyperglycaemia is a major risk factor for future cardiovascular events in patients with acute myocardial infarction. 4 The Euro Heart
Survey on Diabetes and the Heart, which included both patients with acute coronary syndrome and patients with stable angina pectoris, did not find a significant association between impaired glucose regulation (which subsumes IGT and impaired fasting glucose) and cardiovascular risk. 5 Coronary angiography in current clinical practice is the gold standard method to diagnose CAD in high-risk patients. 6 The study of risk factors in angiographied patients therefore is of major clinical interest. The prevalence of post-challenge hyperglycaemia in angiographied coronary patients exceeds 60%. 7, 8 Further,
as we have recently shown, post-challenge hyperglycaemia is associated with the angiographically determined extent of CAD. 7 However, the impact of post-challenge hyperglycaemia on prognosis in patients undergoing coronary angiography for the evaluation of stable CAD remains unclear. We therefore aimed at investigating the impact of post-challenge hyperglycaemia on the incidence of macrovascular events in this clinically important patient population.
Methods
We enrolled 1046 consecutive Caucasian patients who underwent coronary angiography for the routine evaluation of suspected or established stable CAD at the Medical University of Graz or at the Academic Teaching Hospital of Feldkirch between October 1999 and March 2005. The patients were referred for angiography solely on the basis of the clinical indication made by the referring physicians according to current guidelines. 6 Patients who had suffered myocardial infarctions or acute coronary syndromes within 3 months prior to the angiography were not enrolled. Six patients with type 1 diabetes (C-peptide negative) were excluded from the analyses. Venous blood samples were collected after an overnight fast of at least 12 h before angiography was performed and laboratory analyses were performed as described previously. 7 According to American Diabetes Association criteria, 9 patients with a fasting plasma glucose (FPG) ,126 mg/dL (,7.0 mmol/L) and a post-challenge glucose (i.e. plasma glucose 2 h after the 75 g glucose load) ,140 mg/dL (,7.8 mmol/L) were classified as having a normal glucose tolerance (NGT). Impaired glucose tolerance was diagnosed in patients with FPG ,126 (,7.0 mmol/L) mg/dL and post-challenge glucose between 140 and 200 mg/dL (≥7.8 and ,11.1 mmol/L); isolated post-challenge diabetes was diagnosed in patients with a FPG ,126 mg/dL (,7.0 mmol/L) and post-challenge glucose ≥200 mg/dL (≥11.1 mmol/L); and conventional diabetes was diagnosed in patients with FPG ≥126 mg/dL or previously established diabetes. Among patients with established diabetes, 26% were not receiving any glucose lowering medication, and 37, 35, and 32% were receivingalone or in combination-sulfonylurea, biguanides, and insulin, respectively, at baseline. Overall, 71% of our patients were on aspirin, 44% on statins, 3% on fibrates, 12% on calcium antagonists, 55% on beta adrenoreceptor blocking agents, 44% on angiotensin-converting enzyme-inhibitors, and 3% on angiotensin II receptor blocking agents at baseline.
Follow-up data were collected by follow-up visits at our institutions, by telephone contacts with patients and family physicians, and through a national registry of death. Both mortality and the incidence of macrovascular events were recorded. The primary study endpoint was a composite of vascular deaths, non-fatal myocardial infarctions, nonfatal strokes, percutaneous coronary interventions, bypass graftings, and revascularizations of non-coronary arteries, whichever occurred first. Secondary endpoints were (i) overall mortality and (ii) the following three secondary composite endpoints: secondary composite endpoint A, encompassing any death, non-fatal myocardial infarction, non-fatal stroke, percutaneous coronary intervention, bypass grafting, and revascularization of non-coronary arteries; secondary composite endpoint B, encompassing vascular death, non-fatal myocardial infarction, non-fatal stroke, percutaneous coronary intervention, and bypass grafting; and secondary composite endpoint C, encompassing any death, non-fatal myocardial infarction, non-fatal stroke, percutaneous coronary intervention, and bypass grafting.
Contact by telephone led to follow-up and verification of vital status in 97.5%. After review of autopsy, death certificate (ICD-9 codes 434.0-434.9, 410.0-414.9, and 429.2), or hospital charts, an overall number of 52 deaths (57%) were classified vascular and 49 of the vascular deaths (54% of the overall number of deaths) occurred as first vascular events and thus were included in the primary composite study endpoint of first vascular events. Deaths from all other causes were classified as non-vascular.
The Ethics Committee of the University of Innsbruck approved the present study, and informed consent was obtained from all participants.
Statistical analysis
Differences in study variables were tested for statistical significance with the x 2 test for categorical variables, with the unpaired t-test 
Results

Baseline characteristics of the study population
The baseline characteristics of our study population were typical for a cohort undergoing coronary angiography for the evaluation of CAD, with a mean age of 64 + 10 years, a preponderance of male gender (64.0%), a high prevalence of hypertension (78.9%), and a 63.3% prevalence rate of significant coronary stenoses. Three hundred and ninety-four (37.8%) of our patients had an NGT, 280 (26.9%) post-challenge hyperglycaemia, which subsumes IGT (n ¼ 190) together with type 2 diabetes mellitus (T2DM) newly diagnosed solely on the basis of elevated post-challenge glucose in the oGTT (isolated post-challenge diabetes, n ¼ 90), and 366 (35.2%) of our patients had conventional diabetes, i.e. T2DM previously established (n ¼ 244) or newly diagnosed on the basis of fasting glucose values (n ¼ 122). Thus, 62.2% had some abnormality of glycaemia.
Demographic and biochemical characteristics of our patients with respect to the glycaemic state are summarized in Table 1 . Both among patients with post-challenge hyperglycaemia and among patients with conventional diabetes, average age, BMI, and waist circumference were higher, and LDL cholesterol as well as HDL cholesterol were lower when compared with NGT subjects. Further, in patients with post-challenge hyperglycaemia, the prevalence of smoking was lower and patients with conventional diabetes exhibited higher triglycerides than NGT subjects.
The prevalence of angiographically determined CAD and the prevalence of significant coronary stenoses were significantly higher both in patients with post-challenge diabetes and in patients with conventional diabetes when compared with NGT subjects.
Incidence of death and of macrovascular events
Over a mean follow-up period of 3.8 + 1.3 years, we recorded 247 first macrovascular events; thus, 23.8% of our patients suffered the primary endpoint, corresponding to an annual event rate of 6.3%. First events encompassed 49 vascular deaths, 29 non-fatal myocardial infarctions, 24 non-fatal strokes, 95 percutaneous coronary interventions, 22 bypass graftings, and 28 revascularizations of noncoronary arteries. Total mortality was 8.7% (n ¼ 90). The 90 deaths encompassed 46 cardiac deaths, 6 fatal strokes, and 38 non-vascular deaths. The total number of vascular deaths thus was 52; of these, three occurred after another composite of the primary study endpoint and therefore did not count as first vascular events.
Post-challenge hyperglycaemia, conventional diabetes, and macrovascular events Figure 1A shows event-free survival with respect to the glycaemic state. The incidence of macrovascular events in NGT subjects was 18.5%; it was significantly higher in patients with both post-challenge hyperglycaemia (23.6%; P ¼ 0.013) and conventional diabetes (29.5%; P , 0.001). Considering the subgroup of IGT subjects separately, the macrovascular event rate in the 190 IGT patients compared with that in NGT subjects was significantly increased (22.6%; P ¼ 0.035) and was not significantly different from that in the 90 patients with isolated post-challenge diabetes (25.6%; P ¼ 0.817).
The results from univariate analyses were confirmed in Cox regression analyses after adjustment for age, gender, presence of significant coronary stenoses at the baseline angiography, as well as for the non-metabolic syndrome risk factors LDL cholesterol and smoking, with adjusted HRs of 1.46 (95%CI 1.03-2.07, P ¼ 0.033) for patients with post-challenge hyperglycaemia and 1.73 (1.25-2.37, P ¼ 0.001) for those with conventional diabetes.
Impaired glucose tolerance, newly diagnosed diabetes, and macrovascular events
From our study population, 212 patients had newly diagnosed diabetes; this category includes patients with newly diagnosed diabetes irrespective of whether the diagnosis of diabetes was made on the basis of fasting glucose values or on the basis of postchallenge glucose values. diabetes, and established diabetes. When compared with NGT subjects, the macrovascular event rate as described above was significantly increased in IGT patients. It was also higher in patients with newly diagnosed diabetes (22.6%; P ¼ 0.038) and in patients with established diabetes (34.0%; P , 0.001) than in NGT subjects. Importantly, in our cohort of coronary patients, vascular risk was practically identical in patients with IGT and those with newly diagnosed diabetes (P ¼ 0.648). However, IGT patients were at a lower risk than those with established diabetes (P ¼ 0.047).
After adjustment for age, gender, presence of significant coronary stenoses at baseline, as well as for smoking and LDL cholesterol in Cox regression analyses adjusted HRs were 1.51 (1.02-2.22, P ¼ 0.039), 1.39 (0.94-2.05, P ¼ 0.099), and 1.97 (1.39-2.28, P , 0.0010 for patients with IGT, newly diagnosed diabetes, and established diabetes, respectively, when compared with NGT subjects. 
Post-challenge glucose as a continuous variable
Patients with significant coronary stenoses at angiography
The results were consistent in the subgroup of patients with significant coronary stenoses at angiography: The respective adjusted HRs for post-challenge hyperglycaemia in the total study population and in patients with significant CAD were 1.46 (95% CI 1.03-2.07, P ¼ 0.033) and 1.42 (0.96-2.11, P ¼ 0.083); the adjusted HRs for conventional diabetes were 1.73 (1.25-2.37, P ¼ 0.001) in the total study population and 1.85 (1.30-2.64, P ¼ 0.001) in patients with significant CAD at angiography, respectively. Interaction terms hyperglycaemia by significant baseline CAD were not significant (P ¼ 0.743 for post-challenge hyperglycaemia and P ¼ 0.568 for conventional diabetes), indicating that the baseline CAD state did not significantly affect the association between hyperglycaemia and future vascular events.
Secondary study endpoints
As secondary study endpoints, we investigated total mortality and the respective composites of (i) any death, non-fatal myocardial infarction, non-fatal stroke, percutaneous coronary intervention, bypass grafting, and revascularization of non-coronary arteries, (ii) vascular death, non-fatal myocardial infarction, non-fatal stroke, percutaneous coronary intervention, and bypass grafting, and (iii) any death, non-fatal myocardial infarction, non-fatal stroke, percutaneous coronary intervention, and bypass grafting.
As is summarized in Tables 2 and 3 , the results were very similar for these secondary study endpoints as for the primary study endpoint. Irrespective of the endpoint definition, post-challenge hyperglycaemia, and in particular IGT, were associated with a significantly worse outcome than NGT. Most importantly, post-challenge hyperglycaemia indicated an increased overall mortality risk.
Discussion
From our data, we conclude that post-challenge hyperglycaemia confers a strongly increased risk of future macrovascular events in patients undergoing coronary angiography for the evaluation of stable CAD. In particular, vascular risk is already significantly increased in patients with post-challenge hyperglycaemia in the IGT range. Quantitatively, post-challenge hyperglycaemia confers about half the risk increase of established T2DM.
Because of the very high prevalence of post-challenge hyperglycaemia in coronary patients, this finding is of major clinical importance. In our study cohort, post-challenge hyperglycaemia was diagnosed in almost one out of four patients. Concordant with this result, high prevalence rates of post-challenge hyperglycaemia of up to 40% had been described in previous studies addressing glucometabolic disorders in CAD patients. 7, 8, 10, 11 Importantly, about every second subject from the patients with newly diagnosed diabetes and two out of five subjects from the total subgroup of patients with diabetes in our investigation were diagnosed as having diabetes solely on the basis of post-challenge glucose. These data are well in line with the previously reported data from the GAMI trial 12 or from the Euro Heart Survey. 13 Given the major impact of a diagnosis of diabetes on therapeutic decisions in coronary patients, 6 from our data an oGTT appears mandatory for the adequate management of patients with stable CAD. Previously, the DECODE (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) Study Group 2 reported an adverse cardiovascular outcome for unselected patients (not coronary patients) with post-challenge hyperglycaemia. Furthermore, the GAMI-trial, which included 168 patients after acute myocardial infarction showed a markedly increased cardiovascular event rate in patients with post-challenge hyperglycaemia after a median follow up time of 34 months. 4 In contrast, the Euro Heart Survey while confirming that established type 2 diabetes as well as newly detected type 2 diabetes are associated with an increased cardiovascular risk, failed to show an increase in the risk of cardiovascular events for impaired glucose regulation (which includes impaired fasting glycaemia and IGT). Other than our investigation, the Euro Heart Survey analysis did not focus on patients with stable CAD; it further subsumed patients with IGT and those with impaired fasting glucose in a single group, even though these entities were not associated with the same amount of cardiovascular risk in earlier investigations; 2,14 finally and most importantly, the follow-up duration of 1 year in the Euro Heart Survey was very short. Of note, in our study, survival curves started to disperse after 1 year, the time point when the follow-up in the Euro Heart Survey ended. From our data, thus, we conclude that, as in acute coronary syndromes, also in stable CAD post-challenge hyperglycaemia is a marker of increased vascular risk. Post-challenge hyperglycaemia even indicated an increased overall mortality risk.
Post-challenge hyperglycaemia and macrovascular risk: potential mechanisms
Recent trials (ACCORD, ADVANCE) 15, 16 Secondary study endpoints are total mortality and the following three secondary composite endpoints: secondary composite endpoint A, encompassing any death, non-fatal myocardial infarction, non-fatal stroke, percutaneous coronary intervention, bypass grafting, and revascularization of non-coronary arteries; secondary composite endpoint B, encompassing vascular death, non-fatal myocardial infarction, non-fatal stroke, percutaneous coronary intervention, and bypass grafting; and secondary composite endpoint C, encompassing any death, non-fatal myocardial infarction, non-fatal stroke, percutaneous coronary intervention, and bypass grafting. P-values and hazard ratios are given for the comparisons with normal glucose tolerance. Adjusted hazard ratios are adjusted for age, gender, presence of significant coronary stenoses at baseline, smoking, and LDL cholesterol. The Wilcoxon-Gehan statistic was used to compare differences in event rates. Unadjusted and adjusted hazard ratios were derived from Cox proportional hazard models.
thus have put the role of plasma glucose as an independent macrovascular risk factor at debate. Importantly, the targets for glucose lowering therapy were based on HbA1c in these studies, which reflect the mean blood glucose. However, important aspects of glucose metabolism are lost when solely mean blood glucose is taken into consideration. High amplitudes of glucose oscillation have been shown to activate the protein kinase C pathway, 17 inducible nitric oxide synthase, 18 and to induce inflammatory markers 19, 20 much more than elevated but stable glucose levels. Concordantly, recently published data demonstrated that oscillating glucose levels have a significantly more deteriorating effect on endothelial function than elevated, but stable glucose levels. Endothelial dysfunction in turn is a key player in the development of diabetes complications 21 and strongly associated with future cardiovascular events. 22 Also, platelets were shown to be activated not only in diabetes but already in the IGT state. 23 Our observation that post-challenge hyperglycaemia strongly correlates with macrovascular risk in angiographied coronary patients therefore fits well in the existing frame of pathophysiological knowledge.
Strengths and limitations
Important strengths of our investigation are the large sample size, the very high follow-up rate of 97.5%, which is exceptional for an observational study, and the meticulous characterization of study subjects. By design, our study focuses on a selected group of patients; our results from angiographied coronary patients therefore are not necessarily applicable to the general population. In line with recent large intervention trials, we had chosen a combined study endpoint of major vascular events which also included revascularization procedures. The necessity to ascertain sufficient statistical power of course was an important reason behind the selection of this relatively broad combined endpoint. Whatsoever, the constituents of our study endpoint are of unquestionable clinical relevance as indicators of the progression of atherosclerotic disease. The population we chose to investigate is at a high risk for marcovascular events and therefore deserves particular clinical attention and fills the gap between acute coronary syndrome and noncoronary patient cohorts previously described.
Clinical consequences
Several clinical consequences of the present investigation appear important. First, post-challenge hyperglycaemia in the high-risk population of angiographied coronary patients identifies subjects at a particularly high vascular risk. Intensified treatment to decrease macrovascular risk in the identified patients therefore is mandatory. Indeed, the STOP-NIDDM trial showed that lowering post-prandial glucose excursions with acarbose in patients with IGT may improve the cardiovascular outcome. 24 In addition, data from the Euro Heart Survey suggest that glucose-lowering Secondary study endpoints are total mortality, and the following three secondary composite endpoints: secondary composite endpoint A, encompassing any death, non-fatal myocardial infarction, non-fatal stroke, percutaneous coronary intervention, bypass grafting, and revascularization of non-coronary arteries; secondary composite endpoint B, encompassing vascular death, non-fatal myocardial infarction, non-fatal stroke, percutaneous coronary intervention, and bypass grafting; and secondary composite endpoint C, encompassing any death, non-fatal myocardial infarction, non-fatal stroke, percutaneous coronary intervention, and bypass grafting. P-values and hazard ratios are given for the comparisons with normal glucose tolerance. Adjusted hazard ratios are adjusted for age, gender, presence of significant coronary stenoses at baseline, smoking, and LDL cholesterol. The Wilcoxon-Gehan statistic was used to compare differences in event rates. Unadjusted and adjusted hazard ratios were derived from Cox proportional hazard models.
therapy in newly detected diabetes improves prognosis. 25 Overall, however, the available data are insufficient to support the lowering of post-prandial glucose as the main intervention to reduce the risk of macrovascular disease. From the background of currently available evidence, it therefore appears most prudent to strictly enforce treatment goals for other cardiovascular risk factors in the high-risk coronary patients with post-challenge hyperglycaemia, e.g. for LDL cholesterol. Second, because subjects with post-challenge hyperglycaemia in the IGT range are at a high risk of diabetes, 26 diabetes prevention should be a major aim in these patients. Third, two out of five angiographied coronary patients with diabetes are solely diagnosed as having diabetes on the basis of post-challenge hyperglycaemia. Because the diagnosis of diabetes according to current guidelines has a significant impact on the management of CAD patients, 6, 27 this fact alone makes it mandatory to perform oGTTs in angiographied coronary patients.
